Breaking News

Frontida BioPharm Launches Expansion Efforts

Comes on heels of receiving FDA clearance

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

After receiving a closure letter for its Philadelphia manufacturing site on May 4, 2017 from FDA, Frontida BioPharm launched their operations expansion initiatives. The closure letter was received 8 months after the FDA issued a Warning Letter to Frontida based on an FDA inspection of the site occurring between June 15 and July 17, 2015, prior to Frontida’s purchase and operation of the facility. The contract development and manufacturing organization (CDMO) operates the Philadelphia site alo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters